Issue Date: September 7, 2015
Beating Chronic Myeloid Leukemia
The cancer’s name—chronic myeloid leukemia—points to its lingering nature. Many patients with CML live long lives by taking a drug called imatinib. The treatment keeps the cancer in check but does not cure it. Researchers have long suspected that a pool of cancerous stem cells evade this treatment by being quiescent—hibernating to avoid the drug. Now, researchers led by Stéphane Prost of the Institute of Emerging Diseases & Innovative Therapies, in France, and Philippe Leboulch at Harvard Medical School may have found a way to beat those quiescent cancerous cells (Nature 2015, DOI: 10.1038/nature15248). Their trick is to interfere with a cellular pathway that allows the cancerous stem cells to remain quiescent. The team knew that the diabetes drug pioglitazone prods cells out of hibernation, and they speculated that pushing all the stem cells out of quiescence would allow imatinib to finish off the cancer. The strategy seems to have worked. In the three CML patients to whom the team gave imatinib and pioglitazone, the cancer did not return. The team is now pursuing a clinical trial for the combination therapy.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society